OA-13 Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8

IF 2.7 4区医学 Q2 HEMATOLOGY Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01854-8

Meletios Dimopoulos, Meral Beksac, Ludek Pour, Sosana Delimpasi, Vladimir Vorobyev, Hang Quach, Ivan Spicka, Jakub Radocha, Pawel Robak, Kihyun Kim, Michele Cavo, Kazuhito Suzuki, Jodie Wilkes, Kristin Morris, Farrah Pompilus, Molly Purser, Amy Philips-Jones, Xiaoou Zhou, Giulia Fulci, Neal Sule, Suzanne Trudel

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

OA-13 贝兰他单抗马福多汀、泊马度胺和地塞米松与泊马度胺、硼替佐米和地塞米松治疗复发性/难治性多发性骨髓瘤患者：来自 DREAMM-8 的患者报告结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.